Zacks Research Downgrades AxoGen (NASDAQ:AXGN) to Strong Sell

AxoGen (NASDAQ:AXGN) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other research analysts also recently issued reports on the company. Citizens Jmp lifted their price target on AxoGen from $34.00 to $42.00 and gave the company a “market outperform” rating in a report on Tuesday, February 24th. Raymond James Financial reissued an “outperform” rating and issued a $41.00 price objective on shares of AxoGen in a research report on Monday, February 23rd. Wall Street Zen cut AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Citigroup reissued an “outperform” rating on shares of AxoGen in a research report on Tuesday, February 24th. Finally, Lake Street Capital raised their price objective on AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.63.

AxoGen Stock Down 1.5%

Shares of NASDAQ:AXGN traded down $0.62 on Monday, reaching $41.38. The company had a trading volume of 217,415 shares, compared to its average volume of 1,043,096. AxoGen has a 52-week low of $9.22 and a 52-week high of $45.83. The firm’s 50 day simple moving average is $33.36 and its 200-day simple moving average is $30.21. The firm has a market capitalization of $2.15 billion, a PE ratio of -122.27 and a beta of 0.98. The company has a current ratio of 5.11, a quick ratio of 3.31 and a debt-to-equity ratio of 0.51.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.04). AxoGen had a negative net margin of 6.97% and a negative return on equity of 13.44%. The company had revenue of $61.46 million during the quarter, compared to analysts’ expectations of $57.85 million. As a group, analysts expect that AxoGen will post -0.24 earnings per share for the current fiscal year.

Insider Buying and Selling at AxoGen

In other news, insider Erick Wayne Devinney sold 5,221 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $32.84, for a total value of $171,457.64. Following the completion of the sale, the insider owned 262,781 shares of the company’s stock, valued at $8,629,728.04. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.78% of the stock is owned by insiders.

Institutional Trading of AxoGen

A number of institutional investors have recently made changes to their positions in the business. HighMark Wealth Management LLC lifted its position in AxoGen by 88.7% during the 3rd quarter. HighMark Wealth Management LLC now owns 185,085 shares of the medical equipment provider’s stock worth $3,302,000 after acquiring an additional 87,000 shares during the period. Brown Capital Management LLC acquired a new stake in AxoGen during the 3rd quarter worth about $11,500,000. First Eagle Investment Management LLC lifted its position in AxoGen by 142.7% during the 3rd quarter. First Eagle Investment Management LLC now owns 431,843 shares of the medical equipment provider’s stock worth $7,704,000 after acquiring an additional 253,888 shares during the period. Royce & Associates LP acquired a new stake in AxoGen during the 3rd quarter worth about $3,587,000. Finally, SG Americas Securities LLC lifted its position in AxoGen by 459.9% during the 4th quarter. SG Americas Securities LLC now owns 65,480 shares of the medical equipment provider’s stock worth $2,143,000 after acquiring an additional 53,786 shares during the period. Institutional investors and hedge funds own 80.29% of the company’s stock.

Key Headlines Impacting AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Top-line beat: revenue of $61.46M exceeded the Street (~$57.85M), showing continued demand and likely supporting upside in the stock. Axogen, Inc. Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Earnings call / disclosure: management hosted the Q1 call and published the slide deck and transcript — useful for guidance details and cadence but no clear game-changing update in headlines. Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Q1 presentation available — investors can review product metrics, market trends and slides for color on organic growth and cost trends. Axogen, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Neutral Sentiment: Press coverage / snapshot pieces summarizing results provide quick takeaways for traders but add no new fundamentals. AxoGen: Q1 Earnings Snapshot
• Negative Sentiment: EPS missed consensus: reported $0.07 vs. analyst ~$0.11–$0.12, and the company still shows negative net margin/ROE metrics — these profitability misses weigh on earnings-driven investors. AxoGen (AXGN) Q1 Earnings Lag Estimates
• Negative Sentiment: Analyst sentiment turned bearish: Zacks downgraded the stock from “hold” to “strong sell,” which can pressure momentum and broker coverage. Zacks.com
• Negative Sentiment: Guidance ambiguity: filings note an FY2026 guidance update but the published entry lacks a clear EPS target, which may increase near-term uncertainty for investors focused on forward estimates. View Press Release / Slide Deck

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.